By Adam Dorr, Bradd Libby, Owen Westfold and Taylor Hinds

We are entering a new era of healthcare based on a categorically different kind
of medicine whose purpose isn’t just to save us from illness, but to help us be
the best version of ourselves.

Up until now, medicine has been about damage control. Whether it is aspirin for a headache, antibiotics for an infection, or chemotherapy for cancer, we reach for medicine when something has gone wrong. Even preventative medicines like vaccines for infectious disease and statins for heart disease are about avoiding disaster.

Today, the shift has finally begun in earnest toward a new medical paradigm that centers on optimization instead of illness.

RethinkX calls these new medicines health optimizer therapies, or HOTs.

The first new HOTs are blockbuster GLP-1 agonist drugs like semaglutide, better known by its brand names Ozempic and Wegovy. But Ozempic is just the beginning. The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040. The enormous impact of HOTs will reshape economies and societies in fundamental ways. These impacts will be especially pronounced for middle-aged and elderly adults, who will experience HOTs as a stunningly effective anti-aging and rejuvenation therapy.

The convergence of highly-effective glucagon-like peptide-1 receptor agonist drugs (GLP-1s) for fat loss, together with myostatin and activin blocking antibody drugs for muscle gain, is poised to offer something very close to one of the elusive ‘holy grails’  that medical science has pursued for generations: “diet and exercise in a bottle”. And this particular health optimizer therapy is just the beginning...

KEY FINDINGS

💪 Mass Adoption by 2040 – Under medical guidance, over 1 billion adults globally will use personalized HOTs to optimize their health and wellbeing.

💪 "Diet & Exercise in a Bottle" – The first major breakthrough combines GLP-1s (weight loss) with myostatin inhibitors (muscle gain). This duo delivers the results medical science has chased for generations, with even more advanced therapies on the horizon.

💪 A Multi-Industry Earthquake – The disruption is inevitable and will ripple far beyond medicine. Major shifts are coming for food and beverage, agriculture, fitness, insurance, and even the alcohol and tobacco sectors.

💪 Global Prosperity Gains – Beyond individual health, widespread adoption promises massive social, economic, and geopolitical benefits, creating a healthier and more productive global society. 

Want to know more?

Take a look at the full report. 

Browse our webpages. 

CALL TO ACTION

🚀 Nations should immediately enact policy to guarantee affordable, universal access to HOTs for all adults under the supervision of their doctor.

🚀 Nations should fast-track regulatory approval for the development of new HOTs drugs, to help ensure their enormous benefits reach the public as soon as possible.

How you can help?

- Download the report, share it with your network. 

- Get in touch with questions, partnership possibilities. 

Help us spread the word about this transformational disruption.